Shares of QYUNS-B (02509) surged more than 9% during Tuesday morning trading on the Hong Kong Stock Exchange. As of press time, the stock was up 5.60% at HK$17.15, with turnover reaching HK$26.71 million. The rally follows the company's interim financial report, which highlighted the crystallisation of business development (BD) achievements.

QYUNS-B's interim results revealed that out of total operating revenue of RMB 424 million in the first half, authorised licensing agreements contributed RMB 379 million. This includes upfront payments and non-cash consideration from the overseas licensing of TSLP/IL-13 bispecific antibody QX027N, milestone payments for TSLP monoclonal antibody QX008N, and milestone payments for TSLP/IL-33 bispecific antibody QX031N.

According to China Securities, the company's 'QYUNS 1.0' monoclonal antibody pipeline is increasingly bearing fruit. The first commercialised product, ustekinumab biosimilar Sailixin/Saijiening (QX001S), is showing strong sales momentum. Its commercial partner recorded domestic sales exceeding RMB 300 million in the first half of 2026, surpassing last year's full-year figures. Consequently, QYUNS-B generated over RMB 49.5 million in combined revenue from product supply and profit-sharing. Additionally, in May, the product received approval for a new indication to treat Crohn's disease.